利科哈尔科恩A诱导线粒体依赖的亡,并在急性髓性白血病中与venetoclax相互作用
Youhong Li1, Mengting Zhao2, Ye Lin2
1Department of Hematology, The Affiliated People's Hospital of Ningbo University, Ningbo, China; Department of Pathology and Pathogenic Biology, and Zhejiang Key Laboratory of Pathophysiology, School of Basic Medical Sciences, Health Science Center, Ningbo University, Ningbo, China; Institute of Hematology, Ningbo University, Ningbo, China.
European journal of pharmacology
|February 13, 2024
概括
一种天然化合物Licochalcone A (LCA) 有效地降低了急性髓性白血病 (AML) 细胞活力,并诱导了细胞亡. 作为一种治疗剂,LCA显示出前景,提高了venetoclax在AML治疗中的疗效.
科学领域:
- 自然产品化学 自然产品化学
- 血液学 血液学 血液学
- 分子瘤学分子瘤学
背景情况:
- 由于其复杂性和异质性,急性髓性白血病 (AML) 的管理具有挑战性.
- 新型向疗法不可避免地面临阻力,导致不理想的临床结果.
- 自然产品为新型抗白血病疗法提供了有希望的来源.
研究的目的:
- 为了研究Licochalcone A (LCA) 对急性髓性白血病 (AML) 的抗白血病作用.
- 阐明LCA在AML中的作用的潜在分子机制.
- 评估LCA在与现有的AML治疗相结合治疗中的潜力.
主要方法:
- 用LCA治疗人类AML细胞系和初级患者爆发.
- 评估细胞活力,细胞亡和关键蛋白质表达 (MCL-1,BIM,BID,PARP).
- 对信号通路调制 (PI3K/AKT,MAPK) 和c-Myc抑制的分析.
- 在与venetoclax结合使用LCA的评估.
主要成果:
- 以剂量为依赖的LCA降低了AML细胞活力,并诱导了线粒体亡.
- 与亡相关的LCA调节蛋白质 (下调的MCL-1,上调的BIM,截断的BID,切割的PARP).
- LCA抑制了PI3K/AKT和MAPK信号通路,并抑制了c-Myc.
- LCA增强了venetoclax诱导的细胞毒性,并在初级AML爆发中显示出有效性.
结论:
- 利科哈尔科恩A通过诱导亡和途径抑制对AML细胞表现出显著的抗白血病活性.
- LCA显示出作为AML治疗剂的潜力,包括与venetoclax结合使用.
- 这些发现支持进一步调查 AML 治疗策略的 LCA.
相关概念视频
The Intrinsic Apoptotic Pathway
6.5K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.5K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Apoptosis
11.5K
Apoptosis is a combination of two Greek words, 'apo' and 'ptosis,' meaning separation and falling off, respectively. Hippocrates used this word to describe gangrene, which was caused due to bandaging of fractured bones. Apoptosis was distinguished from necrosis in 1970 when John Kerr reported observations of morphological changes occurring during apoptosis. During one experiment, he observed that the disruption of blood supply to the liver tissue resulted in a size...
11.5K
Drugs that Destabilize Microtubules
2.0K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.0K
The Extrinsic Apoptotic Pathway
6.4K
The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
6.4K
Autophagic Cell Death
3.4K
Christian de Duve discovered “autophagy,” a process in which cellular components are engulfed by membrane-bound organelles called autophagosomes. The autophagosomes then fuse with lysosomes to digest the enclosed contents. Autophagy is generally activated in cells to prevent cell death. However, cell death is triggered when the damage is beyond repair.
Autophagy and Apoptosis
Autophagy can activate apoptosis. In normal conditions, the autophagy activating protein Beclin-1 and...
Autophagy and Apoptosis
Autophagy can activate apoptosis. In normal conditions, the autophagy activating protein Beclin-1 and...
3.4K


